Agomab Therapeutics to acquire Origo Biopharma

Belgian Agomab Therapeutics NV is expanding its European footprint by acuiring Barcelona-based fibrosis therapy specialist Origo Biopharma.

Read more

Sofinnova Capital X Fund closed at €472m

Paris-based life sciences venture capital firm Sofinnova Partners has closed the largest early-stage healthcare VC fund in Europe.

Read more

Curevac withdraws MAA of CVnCoV

German CureVac N.V. has withdrawn its application for market approval of its COVID-19 vaccine candidate and will focus on the development of a second-generation vaccine.

Read more

Delivering on Europe´s Green Deal – EFIB 2021 in Vienna

Leading industry leaders, SMEs representatives and academia are joining in Vienna, Austria, at the 14th European Forum for Industrial Biotechnology and the Bioeconomy (EFIB), from 6th to 7th of October, organised by EuropaBio and conference partners.

Read more

COVID-19 immunisation set to get FDA EUA

Pharma giant AstraZeneca has submitted data to the US Food and Drug Administration (FDA) for  Emergency Use Authorization (EUA) of its antibody duo AZD7442.

Read more

Advent France Biotechnology launches €86m fund

Advent France Biotechnology’s has launched a second biotech seed fund with a first close at €86m. Since 2017, the French state fund has financed 15 startups in France, Spain, Belgium and Ireland with €68m.


Read more

Team identifies factors for COVID-19 vaccine protection

A comparison of immune correlates of AstraZeneca’s Phase II/III  COVID-19 vaccine trial shows what antibodiy titer is required to prevent symptomatic disease.

Read more

EIF supports translational med with €25m

The EIF has invested €25m in the Prague-based i&i Biotech Fund I to boost biomedical tech transfer in Austria and Eastern Europe.

Read more

AstraZeneca puts €307m in Irish Alexion plant

Following the $39bn Alexion buy-out completed in July, AstraZeneca plc announced it will invest €307m in the company’s producion site near Dublin.

Read more